Hyperuricemia exacerbates chronic cyclosporine nephropathy

Transplantation

Volumn 71, Issue 7, 2001, Pages 900-905

  Mazzali, Marilda ^a,e   Kim, Yoon Goo ^b   Suga, Shin Ichi ^a   Gordon, Katherine L ^a,e   Kang, Duk Hee ^a,e   Ashley Jefferson, J ^a   Hughes, Jeremy ^a   Kivlighn, Salah D ^c   Lan, Hui Y ^d   Johnson, Richard J ^a,e  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Sungkyunkwan University   (South Korea)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DRUG VEHICLE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXONIC ACID; RENIN; URATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; ENZYME INHIBITION; HISTOPATHOLOGY; HYALINE DEGENERATION; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TISSUE LEVEL; URIC ACID BLOOD LEVEL;

EID: 0035870661     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200104150-00014     Document Type: Article

References (37)

1. Chronic cyclosporine nephropathy. The Achille's heel of immunosuppressive therapy
2. Cyclosporine induced chronic nephropathy: An obliterative microvascular renal injury
3. Reversibility of cyclosporine nephrotoxicity after three months treatment
4. Hyperuricemia after renal transplantation
5. Gout in the heart transplant recipient: Physiological puzzle and therapeutic challenge
6. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients
7. Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients
8. The incidence of gout in renal transplant recipients
9. Hyperuricemia in cyclosporine treated patients: A GFR related effect
10. Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children
11. Impairment of tubular secretion of urate in renal transplant patients on cyclosporine
12. Cyclosporine nephrotoxicity
13. Histopathology of cyclosporine nephrotoxicity
14. Nephrotoxicity of immunosuppressive drugs
15. Prevention of experimental cyclosporine induced interstitial fibrosis by losartan and enalapril
16. Pathogenesis of cyclosporine nephropathy. Roles of angiotensin II and osteopontin
17. Renal handling of uric acid under cyclosporine A treatment
18. Serum uric acid in essential hypertension: An indicator of renal vascular involvement
19. Requiem for gouty nephropathy
20. An evaluation of the pathogenesis of the gout kidney
21. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease and renal disease
22. Uric acid nephropathy and end-stage renal disease. Review of a non-disease
23. Renal function in gout: V. Factors influencing the renal hemodynamics
24. Towards the physiological function of uric acid
25. A preliminary report of nephropathy in hyperuricemic rats
26. Drug interactions and consequences of sodium restriction
27. A modified carbonate phosphotungstate method for the determination of uric acid and comparison with the spectophotometric uricase method
28. Chronic experimental hyperuricemia nephropathy. Biochemical and morphological characterization
29. Acute hyperuricemic nephropathy in rats. An electron microscopy study
30. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis
31. Salt-sensitive hypertension develops after transient exposure to angiotensin II
32. Renal proliferative and phenotypic changes in rats with two-kidney, one-clip Goldblatt hypertension
33. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney
34. The mechanism of hyperuricaemia in cyclosporine-treated renal transplant recipients
35. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use
36. Depressed renal and vascular nitric oxide synthase expression in cyclosporine-induced hypertension
37. Effect of nitric oxide modulation on TGFβ1 and matrix proteins in chronic cyclosporine nephrotoxicity